Biologics have dominated the pharmaceutical industry for years. In 2016, eight of the ten top global best-selling drugs were biologics. This rise of biologics is set to continue, according to a new report by European Pharmaceutical Review www. Biologics are forecast to have $120 billion greater sales than small molecules by 2027.
Nonetheless the tremendous potential of biologic drugs is hampered by short half-lives in vivo, resulting in significantly lower potency than activity seen in vitro. These short-acting therapeutic agents require frequent dosing profiles that can reduce applicability to the clinic, particularly for chronic conditions. Therefore, half-life extension technologies are entering the clinic to enable improved or new biologic therapies. PEGylation is the first successful technology to improve pharmacokinetic profiles of therapeutic agents and has been applied in the clinic for over 33 years.
However, Pegylated enzymes are associated with severe immune-mediated adverse reactions and anaphylaxis! Effective treatments against oncology and genetic diseases; Rius Medical is ideally positioned to make a difference for those patients with enormous unmet medical need that cannot be helped today. That’s right, improved Biologics for effective treatments (i.e. enzyme-biologics) against oncology and genetic diseases is the primary focus of Rius Medical. [More info on the PDF download]
Don’t hesitate to reach out for more information as an investor actively seeking to finance Life Science innovation! Rius Medical solves the scientific and technical hurdles blocking access to life changing protein therapeutics (enzyme or antigen biologics) by “reprogramming stem cells” into cell therapies.
Many thanks and warmest regards,
Founder and CEO